Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06183528

Effects of Pericapsular Nerve Group Block on Postoperative Recovery for Total Hip Arthroplasty

The hypothesis of this study is that patients who undergo PENG block in before Total Hip Artroplasthy (THA) surgery with spinal anesthesia will have reduced postoperative pain scores, less need for opioid analgesics and earlier mobilisation.

Recruiting

Interested in participating?

Request Info

Key information

Age range

40 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

UmraniyeERH

Istanbul, Umraniye, 34734, Turkey (Türkiye)

Location status: Recruiting

Location contact

zeliha tuncel, ass prof

CONTACT

[email protected]

+905053577483

About this study

This prospective randomised controlled study included a total of 60 patients aged 40-85 years who underwent THA surgery under spinal anaesthesia. Patients were divided into two groups as PENG block (n:30) and non-PENG block (n:30). PENG block was placed in the fascial plane between the pseudotendon and pubic ramus with USG in-plane technique, 20 ml of 0.5% bupivacaine was administered and surgery was initiated. The primary outcome of the study was to investigate the effect of preoperative PENG block application on postoperative pain, opioid requirement, mobilisation time, hip joint patency and length of hospital stay in patients undergoing THA surgery. The secondary outcome was to investigate the effect of PENG block on perioperative haemodynamics and postoperative side effects.

For multimodal analgesia, 10 ml 0.5% bupivacaine + 10 ml 2% lidocaine is infiltrated into the surgical wound incision line by the surgical team at the end of surgery. After tramadol 50 mg loading with PCA device, a basal rate of 5-10 mg/hour (20 mg bolus dose + 30 minutes lock time) is given with paracetamol 10 mg/kg iv (8 hours interval).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • THA performed by posterior approach
  • 40-85 age range
  • ASA 1-3

Exclusion criteria

Under 40 years of age, over 85 years of age,

  • ASA 4 and above,
  • Cognitive impairment (Alzheimer's disease, dementia, delirium etc.),
  • Hip fracture,
  • Application site infection,
  • Allergy to local anaesthetic agents,
  • Patients are non-consenting patients.

Treatment and study plan

pericapsular nerve group (PENG) block

Procedure

With ultrasonography-guided PENG block, the femoral, obturator and accessory obturator nerve branches that provide sensory innervation of the anterior surface of the hip joint capsule are blocked .

Primary outcomes

  1. postoperative pain score

    Time frame: recovery room 30 min, 12., 24. and 48. hours in the postoperative period

    VAS pain score

  2. mobilisation time

    Time frame: 24 -48 hours

    walking 5 steps with walker

  3. hip joint patency

    Time frame: 24. hours

    Measurement of joint movement angle with goniometer (angle)

  4. total opioid consumption

    Time frame: 48 hours

    Tramadol total usage (mg)

Secondary outcomes

  1. PENG block side effects

    Time frame: The first 48 hours after performing the PENG block

    motor block, nausea, vomiting, anaphylaxis, nerve damage

  2. Perioperative haemodynamic data

    Time frame: T1: 30 minutes (min) after spinal anesthesia, T2: at the end of the surgical procedure, T3: at 30 minutes after recovery

    heart rate, mean arterial pressure

  3. length of hospital stay

    Time frame: day

    hospitalization and discharge time for surgery

Study contacts

Contact information is provided by the study sponsor or research team.

hale arkan tuna, specialist dr

CONTACT

[email protected]

+905303705619

zeliha tuncel, ass prof

CONTACT

[email protected]

+905053577483

Sponsors and collaborators

Lead sponsor

Umraniye Education and Research Hospital

Other Gov

Registry information

Important dates

Study start
2023
Primary completion
2024
Study completion
2025
First posted
Dec 27, 2023
Registry last updated
Nov 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.